Novoseven

Known as: Novo Seven 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2003
2003
CARDIAC surgery with cardiopulmonary bypass (CPB) poses serious hemostatic challenges in Jehovah’s Witnesses, who refuse blood… (More)
  • figure 1
Is this relevant?
2003
2003
Diffuse bleeding during neurosurgical operations is a major complication that can be difficult to control. In extreme… (More)
Is this relevant?
Review
2002
Review
2002
Recombinant activated factor VII (rFVIIa, 'NovoSeven') is indicated for the treatment of spontaneous and surgical bleeding in… (More)
Is this relevant?
Review
2000
Review
2000
Recombinant activated factor VII (rFVIIa, NovoSeven) was first developed for treating those haemophilia patients with inhibitors… (More)
Is this relevant?
2000
2000
Haemorrhages represent a major complication of treatment with vitamin K antagonists. In cases of severe bleeding, a prompt effect… (More)
Is this relevant?
2000
2000
The development of inhibitors in haemophilia patients is one of the most serious challenges to effective treatment. The effect of… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Recombinant factor VIIa (rFVIIa: NovoSeven; Novo Nordisk) has proven efficacy in the treatment of haemophilic patients with… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Vitamin K antagonists are most commonly used in long-term thrombosis prophylaxis and the use in patients with cardiovascular… (More)
Is this relevant?
1996
1996
The concept of using factor VIIa (FVIIa) to induce hemostasis in hemophilia is new and takes advantage of the normal tissue… (More)
Is this relevant?